StockNews.com Initiates Coverage on Aethlon Medical (NASDAQ:AEMD)

Stock analysts at StockNews.com began coverage on shares of Aethlon Medical (NASDAQ:AEMD) in a research report issued to clients and investors on Sunday. The brokerage set a “sell” rating on the medical equipment provider’s stock.

Separately, HC Wainwright restated a “buy” rating and set a $7.00 price objective on shares of Aethlon Medical in a research note on Friday, November 15th.

Aethlon Medical Price Performance

AEMD opened at $0.40 on Friday. Aethlon Medical has a 12-month low of $0.24 and a 12-month high of $2.35. The firm’s fifty day moving average price is $0.40 and its 200 day moving average price is $0.44. The stock has a market capitalization of $5.63 million, a PE ratio of -0.14 and a beta of 1.74.

About Aethlon Medical

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.